SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities

Theochari, E; Cock, HR; Lozsadi, D; Galtrey, C; Arevalo, J; Mula, M (2019) Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. EPILEPSY & BEHAVIOR, 90. pp. 129-131. ISSN 1525-5050 https://doi.org/10.1016/j.yebeh.2018.11.032
SGUL Authors: Cock, Hannah Rutherford Mula, Marco

[img] Microsoft Word (.docx) Accepted Version
Restricted to Repository staff only until 7 December 2019.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (45kB)

Abstract

This is a case series of 25 patients with drug-resistant epilepsy and psychiatric comorbidities started on Brivaracetam (BRV) at St George’s University Hospitals and Frimley Health in London. Median BRV dose was 125 mg for a median follow period of 8 months. Nineteen had focal epilepsy, four had generalized epilepsies and one had unclassified epilepsy; 76% had mood disorders (either depression or bipolar disorder), 12% intellectual disabilities with autism spectrum disorder and challenging behavior and 12% psychoses. 40% of patients presented at least 50% seizure reduction but none of them became seizure free. A total of 44% patients discontinued BRV, 20% because of adverse events, 20% because of inefficacy and 4% because of both. Depression was reported by 8%, aggressive behavior by 8% while 4% reported both. A total of 91.6% had received Levetiracetam (LEV) before, in whom LEV was discontinued because of psychiatric adverse events (PAEs) in half. 77% of patients who developed PAEs with LEV didn’t do so on BRV suggesting that BRV is better tolerated than LEV in complex patients with psychiatric comorbidities and that the SV2A protein modulation is unlikely to be implicated in LEV-related PAEs.

Item Type: Article
Additional Information: © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: 1103 Clinical Sciences, Neurology & Neurosurgery
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Innovation & Development in Education (INMEID)
Journal or Publication Title: EPILEPSY & BEHAVIOR
ISSN: 1525-5050
Dates:
DateEvent
January 2019Published
7 December 2018Published Online
22 November 2018Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
URI: http://openaccess.sgul.ac.uk/id/eprint/110416
Publisher's version: https://doi.org/10.1016/j.yebeh.2018.11.032

Actions (login required)

Edit Item Edit Item